These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

1168 related articles for article (PubMed ID: 15935475)

  • 1. Dopaminergic modulation of cognitive function-implications for L-DOPA treatment in Parkinson's disease.
    Cools R
    Neurosci Biobehav Rev; 2006; 30(1):1-23. PubMed ID: 15935475
    [TBL] [Abstract][Full Text] [Related]  

  • 2. Dopaminergic effects on cognitive performance in patients with Parkinson's disease.
    Lange KW; Paul GM; Naumann M; Gsell W
    J Neural Transm Suppl; 1995; 46():423-32. PubMed ID: 8821078
    [TBL] [Abstract][Full Text] [Related]  

  • 3. The role of dopamine in cognitive sequence learning: evidence from Parkinson's disease.
    Shohamy D; Myers CE; Grossman S; Sage J; Gluck MA
    Behav Brain Res; 2005 Jan; 156(2):191-9. PubMed ID: 15582105
    [TBL] [Abstract][Full Text] [Related]  

  • 4. Peculiarities of L: -DOPA treatment of Parkinson's disease.
    Kostrzewa RM; Nowak P; Kostrzewa JP; Kostrzewa RA; Brus R
    Amino Acids; 2005 Mar; 28(2):157-64. PubMed ID: 15750845
    [TBL] [Abstract][Full Text] [Related]  

  • 5. Levodopa enhances synaptic plasticity in the substantia nigra pars reticulata of Parkinson's disease patients.
    Prescott IA; Dostrovsky JO; Moro E; Hodaie M; Lozano AM; Hutchison WD
    Brain; 2009 Feb; 132(Pt 2):309-18. PubMed ID: 19050033
    [TBL] [Abstract][Full Text] [Related]  

  • 6. Levodopa in the early treatment of Parkinson's disease.
    Murata M
    Parkinsonism Relat Disord; 2009 Jan; 15 Suppl 1():S17-20. PubMed ID: 19131036
    [TBL] [Abstract][Full Text] [Related]  

  • 7. L-DOPA: a scapegoat for accelerated neurodegeneration in Parkinson's disease?
    Lipski J; Nistico R; Berretta N; Guatteo E; Bernardi G; Mercuri NB
    Prog Neurobiol; 2011 Sep; 94(4):389-407. PubMed ID: 21723913
    [TBL] [Abstract][Full Text] [Related]  

  • 8. The 'magic' of L-dopa: why is it the gold standard Parkinson's disease therapy?
    Mercuri NB; Bernardi G
    Trends Pharmacol Sci; 2005 Jul; 26(7):341-4. PubMed ID: 15936832
    [TBL] [Abstract][Full Text] [Related]  

  • 9. Opioids and motor complications in Parkinson's disease.
    Samadi P; Bédard PJ; Rouillard C
    Trends Pharmacol Sci; 2006 Oct; 27(10):512-7. PubMed ID: 16908075
    [TBL] [Abstract][Full Text] [Related]  

  • 10. Treatment strategies in Parkinson's disease after a quarter century experiences with L-DOPA therapy.
    Fischer PA
    J Neural Transm Suppl; 1995; 46():381-9. PubMed ID: 8821073
    [TBL] [Abstract][Full Text] [Related]  

  • 11. [Levodopa and cognitive disorders in Parkinson's disease].
    Leiva-Santana C; Alvarez-Saúco M
    Rev Neurol; 2006 Jul 16-31; 43(2):95-100. PubMed ID: 16838257
    [TBL] [Abstract][Full Text] [Related]  

  • 12. Dopaminergic basis for deficits in working memory but not attentional set-shifting in Parkinson's disease.
    Lewis SJ; Slabosz A; Robbins TW; Barker RA; Owen AM
    Neuropsychologia; 2005; 43(6):823-32. PubMed ID: 15716155
    [TBL] [Abstract][Full Text] [Related]  

  • 13. The dopamine agonist piribedil with L-DOPA improves attentional dysfunction: relevance for Parkinson's disease.
    Turle-Lorenzo N; Maurin B; Puma C; Chezaubernard C; Morain P; Baunez C; Nieoullon A; Amalric M
    J Pharmacol Exp Ther; 2006 Nov; 319(2):914-23. PubMed ID: 16920993
    [TBL] [Abstract][Full Text] [Related]  

  • 14. Dopaminergic modulation of cognitive interference after pharmacological washout in Parkinson's disease.
    Fera F; Nicoletti G; Cerasa A; Romeo N; Gallo O; Gioia MC; Arabia G; Pugliese P; Zappia M; Quattrone A
    Brain Res Bull; 2007 Sep; 74(1-3):75-83. PubMed ID: 17683792
    [TBL] [Abstract][Full Text] [Related]  

  • 15. [Benefit of L-DOPA-without-DCI (decarboxylase inhibitor) therapy on wearing-off phenomenon in advanced stages of Parkinson's disease patients].
    Hironishi M; Miwa H; Kondo T
    No To Shinkei; 2002 Feb; 54(2):127-32. PubMed ID: 11889758
    [TBL] [Abstract][Full Text] [Related]  

  • 16. Synaptic dysfunction in Parkinson's disease.
    Bagetta V; Ghiglieri V; Sgobio C; Calabresi P; Picconi B
    Biochem Soc Trans; 2010 Apr; 38(2):493-7. PubMed ID: 20298209
    [TBL] [Abstract][Full Text] [Related]  

  • 17. Brain dopaminergic modulation associated with executive function in Parkinson's disease.
    Farid K; Sibon I; Guehl D; Cuny E; Burbaud P; Allard M
    Mov Disord; 2009 Oct; 24(13):1962-9. PubMed ID: 19672989
    [TBL] [Abstract][Full Text] [Related]  

  • 18. Dementia and treatment with L-dopa in Parkinson's disease.
    Hietanen M; Teräväinen H
    Mov Disord; 1988; 3(3):263-70. PubMed ID: 3193964
    [TBL] [Abstract][Full Text] [Related]  

  • 19. Neuroprotective and neurotoxic roles of levodopa (L-DOPA) in neurodegenerative disorders relating to Parkinson's disease.
    Kostrzewa RM; Kostrzewa JP; Brus R
    Amino Acids; 2002; 23(1-3):57-63. PubMed ID: 12373519
    [TBL] [Abstract][Full Text] [Related]  

  • 20. [Hallucinations in Parkinson's disease].
    Moser A; Hagenah J; Kömpf D
    Nervenarzt; 2003 Apr; 74(4):376-85, quiz 385-6. PubMed ID: 12707709
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 59.